Trial
NCT01658527
TAK-700 in Castration Resistant Prostate Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Prostate Cancer
Intervention
Orteronel
Why stopped
Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-10